Start-Ups with Predictive ADME/Tox Technologies
This article was originally published in Start Up
Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.
You may also be interested in...
Given the current "Safety First" mind-set among regulators, it's not surprising that the field of predictive toxicology has been slow to gain traction. Despite significant progress in developing biomarkers, database tools, and other methods, pharma companies continue to rely heavily on traditional methods for assessing potential drug toxicities. Even if investors are shy now, many say that they will eventually be a beneficiary of predictive toxicology, and that comes as good news to start-ups in the space.
Qualyst Inc. offers its ADME and toxicology technologies not on a service model, but as a licensing model for technology and transfer to drug developers. The most fully developed of Qualyst's technologies is B-Clear, which it says is the only in vitro model available to industry today that is predictive of in vivo biliary clearance and excretion.
By combining quantum chemistry and computing power, QuantumBio Inc. says it can model large macromolecules far better and more efficiently than currently available mechanics-based software. The company's tools promise better predictability of chemical and physical properties for virtual screening, QSAR, ADME/Tox, lead optimization and docking.